Edinburgh-based cell analysis startup Cytomos has raised £4m in a round led by Scottish angel network Archangels.
The Scottish firm said it will use the capital injection to scale up its dielectric spectroscopy technology, which aims to bring therapies to market faster.
Use cases range from drug development, gene therapy manufacturing and bioprocessing. Cytomos is aiming to commercialise its cell platform next year and further grow its team.
Cytomos made three appointments to its leadership team in October in preparation for its upcoming Series A, HQ relocation and development of its product.
“Its ambitious vision to improve real-time cell analysis in formats to better suit the end users will revolutionise the development and commercialisation of products in the bioprocessing and cell and gene therapies spaces,” said Archangels’ director and head of new investments Sarah Hardy.
Old College Capital, Scottish Enterprise and British Business Bank also invested in the round.
“We are uniquely positioned in harnessing the power of consumer electronics technology to meet the emerging, complex needs of the bioprocess industry,” said Cytomos chief executive David Rigterink.
The company scooped £1.6m in seed funding for its cell platform in June last year.
Archangels this month signed a co-investment agreement with British Business Investments worth £12m.